Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update

J. Tajti, Délia Szok, Anett Csáti, L. Vécsei

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Migraine as a highly disabling pain condition influences the daily activities of those affected, including children and adolescents. The pathomechanism of migraine is not fully understood, and the different types of prophylactic antimigraine drugs that are applied are not specific for migraine. There is a need for preventive treatment in the event of frequent migraine attacks, an impairment of the quality of life, severe accompanying or aura symptoms, and the failure of acute drug treatment. The following pharmacological classes are recommended: antidepressants, antiepileptics, antihistamines, beta-adrenergic receptor blockers, and calcium ion channel antagonists, besides onabotulinum toxin A and nutraceuticals (butterbur). The most urgent goal as concerns pharmaceutical innovation is the development of pathomechanism-based antimigraine drugs and personalized therapy tailored to the children and adolescents.

Original languageEnglish
Article number1
Pages (from-to)1-9
Number of pages9
JournalCurrent Pain and Headache Reports
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Migraine Disorders
Pharmaceutical Preparations
Petasites
Adrenergic beta-Antagonists
Histamine Antagonists
Receptors, Adrenergic, beta
Calcium Channel Blockers
Calcium Channels
Therapeutics
Dietary Supplements
Anticonvulsants
Antidepressive Agents
Epilepsy
Quality of Life
Pharmacology
Drug Therapy
Pain

Keywords

  • Antidepressants
  • Antiepileptics
  • Antihistamines
  • Beta-adrenergic receptor blockers
  • Butterbur
  • Calcium ion channel antagonists
  • Efficacy
  • Migraine
  • Onabotulinum toxin A
  • Pediatric
  • Prophylactic
  • Safety
  • Therapy
  • Tolerability

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Prophylactic Drug Treatment of Migraine in Children and Adolescents : An Update. / Tajti, J.; Szok, Délia; Csáti, Anett; Vécsei, L.

In: Current Pain and Headache Reports, Vol. 20, No. 1, 1, 01.01.2016, p. 1-9.

Research output: Contribution to journalArticle

@article{d308c4aa27644a7b9e04c4a9242b53e7,
title = "Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update",
abstract = "Migraine as a highly disabling pain condition influences the daily activities of those affected, including children and adolescents. The pathomechanism of migraine is not fully understood, and the different types of prophylactic antimigraine drugs that are applied are not specific for migraine. There is a need for preventive treatment in the event of frequent migraine attacks, an impairment of the quality of life, severe accompanying or aura symptoms, and the failure of acute drug treatment. The following pharmacological classes are recommended: antidepressants, antiepileptics, antihistamines, beta-adrenergic receptor blockers, and calcium ion channel antagonists, besides onabotulinum toxin A and nutraceuticals (butterbur). The most urgent goal as concerns pharmaceutical innovation is the development of pathomechanism-based antimigraine drugs and personalized therapy tailored to the children and adolescents.",
keywords = "Antidepressants, Antiepileptics, Antihistamines, Beta-adrenergic receptor blockers, Butterbur, Calcium ion channel antagonists, Efficacy, Migraine, Onabotulinum toxin A, Pediatric, Prophylactic, Safety, Therapy, Tolerability",
author = "J. Tajti and D{\'e}lia Szok and Anett Cs{\'a}ti and L. V{\'e}csei",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s11916-015-0536-6",
language = "English",
volume = "20",
pages = "1--9",
journal = "Current Pain and Headache Reports",
issn = "1531-3433",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Prophylactic Drug Treatment of Migraine in Children and Adolescents

T2 - An Update

AU - Tajti, J.

AU - Szok, Délia

AU - Csáti, Anett

AU - Vécsei, L.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Migraine as a highly disabling pain condition influences the daily activities of those affected, including children and adolescents. The pathomechanism of migraine is not fully understood, and the different types of prophylactic antimigraine drugs that are applied are not specific for migraine. There is a need for preventive treatment in the event of frequent migraine attacks, an impairment of the quality of life, severe accompanying or aura symptoms, and the failure of acute drug treatment. The following pharmacological classes are recommended: antidepressants, antiepileptics, antihistamines, beta-adrenergic receptor blockers, and calcium ion channel antagonists, besides onabotulinum toxin A and nutraceuticals (butterbur). The most urgent goal as concerns pharmaceutical innovation is the development of pathomechanism-based antimigraine drugs and personalized therapy tailored to the children and adolescents.

AB - Migraine as a highly disabling pain condition influences the daily activities of those affected, including children and adolescents. The pathomechanism of migraine is not fully understood, and the different types of prophylactic antimigraine drugs that are applied are not specific for migraine. There is a need for preventive treatment in the event of frequent migraine attacks, an impairment of the quality of life, severe accompanying or aura symptoms, and the failure of acute drug treatment. The following pharmacological classes are recommended: antidepressants, antiepileptics, antihistamines, beta-adrenergic receptor blockers, and calcium ion channel antagonists, besides onabotulinum toxin A and nutraceuticals (butterbur). The most urgent goal as concerns pharmaceutical innovation is the development of pathomechanism-based antimigraine drugs and personalized therapy tailored to the children and adolescents.

KW - Antidepressants

KW - Antiepileptics

KW - Antihistamines

KW - Beta-adrenergic receptor blockers

KW - Butterbur

KW - Calcium ion channel antagonists

KW - Efficacy

KW - Migraine

KW - Onabotulinum toxin A

KW - Pediatric

KW - Prophylactic

KW - Safety

KW - Therapy

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84951145066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951145066&partnerID=8YFLogxK

U2 - 10.1007/s11916-015-0536-6

DO - 10.1007/s11916-015-0536-6

M3 - Article

C2 - 26695061

AN - SCOPUS:84951145066

VL - 20

SP - 1

EP - 9

JO - Current Pain and Headache Reports

JF - Current Pain and Headache Reports

SN - 1531-3433

IS - 1

M1 - 1

ER -